BridgeMD
New treatment option for Secondary Prevention of Coronary Heart Disease
Official title Intelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients
ClinicalTrials.gov ID: NCT07259278
What this study is testing
What is AI-Enabled Stratified Management System?
AI-Enabled Stratified Management System is an investigational medicine, given as an once-daily, being studied as a potential treatment for secondary prevention of coronary heart disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to find out if an artificial intelligence (AI)-enabled stratified management platform can help adults with coronary heart disease (CHD) better perform exercise rehabilitation and manage their health after being discharged from the hospital. The main questions it aims to answer are: 1.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- CHD patients aged over 18 years;
- Stratified as low-risk for cardiovascular events during exercise and classified as low-risk according to the GRACE risk score.
- Ability of the patient or close relatives to use smartphones and applications;
- Willingness to participate and sign the informed consent form.
You likely can't join if
- Residual stenosis of \>50% in the left main coronary artery, or \>70% stenosis in other major epicardial vessels;
- Planned coronary revascularization within the next 3 months;
- Acute myocardial infarction within the past 1 month;
- Severe cognitive impairment;
- Severely impaired exercise capacity.
- Advanced-stage malignancy;
See the full eligibility criteria
- CHD patients aged over 18 years;
- Stratified as low-risk for cardiovascular events during exercise and classified as low-risk according to the GRACE risk score.
- Ability of the patient or close relatives to use smartphones and applications;
- Willingness to participate and sign the informed consent form.
- Residual stenosis of \>50% in the left main coronary artery, or \>70% stenosis in other major epicardial vessels;
- Planned coronary revascularization within the next 3 months;
- Acute myocardial infarction within the past 1 month;
- Severe cognitive impairment;
- Severely impaired exercise capacity.
- Advanced-stage malignancy;
- Life expectancy less than 3 months;
- Severe multi-organ failure;
- Other conditions deemed unsuitable for home-based exercise rehabilitation following assessment by a specialist rehabilitation physician.
- Refusal to provide written informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.